Trial Profile
A Randomized, Double-blind, Placebo-controlled, Mono-center Study to Evaluate the Effects of Mepolizumab on Airway Physiology in Patients With Eosinophilic Asthma: the MEMORY Study
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms MEMORY
- 04 Jun 2017 Status changed from active, no longer recruiting to discontinued.
- 28 Apr 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2017.
- 10 Oct 2016 Planned End Date changed from 1 Mar 2017 to 1 Aug 2018.